EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Glyburide confers neuroprotection against age-related macular degeneration (AMD)

Emilie Picard, Jenny Youale, Max J Hyman, Edward Xie, Seiki Achiedo, Gabriel T Kaufmann, John Moir, Alejandra Daruich, Patricia Crisanti, Alicia Torriglia, Michel Polak, Francine Behar-Cohen und 2 weitere

Translational Research · 2024-10 · 272 · 81-94

DOI: 10.1016/j.trsl.2024.05.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2024-10. Verfasst von Emilie Picard und 13 weiteren Autor:innen. Beteiligte Einrichtung: Inserm UMRS1138, Team 1: Physiopathology of ocular diseases-Therapeutic innovations, Centre de Recherche des Cordeliers, Paris, France; Sorbonne Univ…. Hauptthemen laut MEDLINE: Glyburide, Macular Degeneration, Neuroprotective Agents, Oxidative Stress. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glyburide, a sulfonylurea drug used to treat type 2 diabetes, boasts neuroprotective effects by targeting the sulfonylurea receptor 1 (SUR1) and associated ion channels in various cell types, including those in the central nervous system and the retina. Previously, we demonstrated that glyburide therapy improved retinal function and structure in a rat model of diabetic retinopathy. In the present study, we explore the application of glyburide in non-neovascular ("dry") age-related macular degeneration (AMD), another progressive disease characterized by oxidative stress-induced damage and neuroinflammation that trigger cell death in the retina. We show that glyburide administration to a human cone cell line confers protection against oxidative stress, inflammasome activation, and apoptosis. To corroborate our in vitro results, we also conducted a case-control study, controlling for AMD risk factors and other diabetes medications. It showed that glyburide use in patients reduces the odds of new-onset dry AMD. A positive dose-response relationship is observed from this analysis, in which higher cumulative doses of glyburide further reduce the odds of new-onset dry AMD. In the quest for novel therapies for AMD, glyburide emerges as a promising repurposable drug given its known safety profile. The results from this study provide insights into the multifaceted actions of glyburide and its potential as a neuroprotective agent for retinal diseases; however, further preclinical and clinical studies are needed to validate its therapeutic potential in the context of degenerative retinal disorders such as AMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlyburideMacular DegenerationNeuroprotective AgentsOxidative StressHumansMaleFemaleApoptosisAgedCell LineCase-Control StudiesRetinal Cone Photoreceptor CellsNeuroprotectionInflammasomes

Stichwörter der Autor:innen

Age-related macular degeneration (AMD)Dry AMDGlibenclamideGlyburideRetinal neuroprotectionSulfonylureaSulfonylurea Receptor-1 (SUR1)photoreceptorsretinal apoptosisretinal degenerationretinal oxidative stress

Substanzen

GlyburideNeuroprotective AgentsInflammasomes

Autor:innen und Institutionen

  • Inserm UMRS1138, Team 1: Physiopathology of ocular diseases-Therapeutic innovations, Centre de Recherche des Cordeliers, Paris, France; Sorbonne Université UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France;…
  • enter for Health and the Social Sciences, University of Chicago, Chicago, Illinois.
  • Stony Brook University Hospital, Stony Brook, NY.
  • Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
  • Pritzker School of Medicine, University of Chicago, Chicago, Illinois.
  • AP-HP, Service d'endocrinologie, diabétologie et gynécologie pédiatriques, Hôpital universitaire Necker-Enfants Malades, Paris, France; Inserm U1016, Institut Cochin, Paris, France; Inserm UMR 1163, Institut Imagine, Un…

Förderung

  • Agence Nationale de la Recherche

Zitieren

APA

Picard, E., Youale, J., Hyman, M. J., Xie, E., Achiedo, S., Kaufmann, G. T., Moir, J., Daruich, A., Crisanti, P., Torriglia, A., Polak, M., Behar-Cohen, F., Skondra, D., & Berdugo, M. (2024). Glyburide confers neuroprotection against age-related macular degeneration (AMD). Translational Research, 272, 81-94. https://doi.org/10.1016/j.trsl.2024.05.002

Vancouver

Picard E, Youale J, Hyman MJ, Xie E, Achiedo S, Kaufmann GT, et al. Glyburide confers neuroprotection against age-related macular degeneration (AMD). Translational Research. 2024;272:81-94. doi:10.1016/j.trsl.2024.05.002

BibTeX
@article{Picard2024,
  author = {Picard, Emilie and Youale, Jenny and Hyman, Max J and Xie, Edward and Achiedo, Seiki and Kaufmann, Gabriel T and Moir, John and Daruich, Alejandra and Crisanti, Patricia and Torriglia, Alicia and Polak, Michel and Behar-Cohen, Francine and Skondra, Dimitra and Berdugo, Marianne},
  title = {Glyburide confers neuroprotection against age-related macular degeneration (AMD)},
  journal = {Translational Research},
  year = {2024},
  volume = {272},
  pages = {81--94},
  doi = {10.1016/j.trsl.2024.05.002}
}
Kostenlos starten →